Free Technical Briefing on Drug Makers Stocks -- GW Pharma, AbbVie, AstraZeneca, and Bristol-Myers Squibb
NEW YORK, July 26, 2018 /PRNewswire/ --
If you want a free Stock Review on GWPH, ABBV, AZN, and BMY sign up now at https://stocktraderreport.com/registration/. On Wednesday, July 25, 2018, with all sectors in the green at the end of the trading sessions, US markets experienced broad based gains. Benchmark US indices were bullish at the end of yesterday's session - NASDAQ Composite was up 1.17%, closing at 7,932.24; the Dow Jones Industrial Average was 0.68% higher, finishing at 25,414.10; and the S&P 500 ended at 2,846.07, up 0.91%. Pre-market today, StockTraderReport.com scans the performance of the following four Drug Manufacturers - Major stocks: GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH), AbbVie Inc. (NYSE: ABBV), AstraZeneca PLC (ADR) (NYSE: AZN), and Bristol-Myers Squibb Co. (NYSE: BMY). All you have to do is sign up today for this free limited time offer by clicking the link below.
https://stocktraderreport.com/registration/
GW Pharmaceuticals
On Wednesday, shares in United Kingdom-headquartered GW Pharmaceuticals PLC recorded a trading volume of 216,043 shares. The stock ended at $141.51, declining 0.26% from the last trading session. The Company's shares have gained 22.47% in the last twelve months. The stock is trading above its 200-day moving average by 8.60%. Furthermore, shares of GW Pharmaceuticals, which engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant, have a Relative Strength Index (RSI) of 38.77.
On July 23rd, 2018, GW Pharma said that it will announce its Q3 financial results for the period ending June 30th, 2018, on August 07th, 2018. The Company will host a conference call on the same day at 4:30 p.m. EDT. Conference call information will be provided in the financial results press release. Get the full research report on GWPH for free by clicking below at:
https://stocktraderreport.com/registration/?symbol=GWPH
AbbVie
USA-based AbbVie Inc.'s stock finished yesterday's session 1.73% higher at $93.12. A total volume of 7.48 million shares was traded. The Company's shares have gained 28.41% in the last twelve months. The stock is trading below its 50-day moving average by 4.85%. Furthermore, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 45.79 and have a dividend yield of 4.12%.
On July 24th, 2018, AbbVie announced that the US FDA approved ORILISSA™ (elagolix), the first and only oral gonadotropin-releasing hormone antagonist specifically developed for women with moderate to severe endometriosis pain. The FDA approved ORILISSA under priority review. ABBV's complimentary research coverage is a few simple steps away at:
https://stocktraderreport.com/registration/?symbol=ABBV
AstraZeneca
At the close of trading on Wednesday, shares in United Kingdom-based AstraZeneca PLC saw a rise of 0.05%, ending the day at $37.44. The stock recorded a trading volume of 2.71 million shares. The Company's shares have advanced 10.83% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 3.38% and 7.25%, respectively. Moreover, shares of AstraZeneca, which discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide, have an RSI of 63.91 and have a dividend yield of 3.74%. Register for your free research report on AZN at:
https://stocktraderreport.com/registration/?symbol=AZN
Bristol-Myers Squibb
USA-headquartered Bristol-Myers Squibb Co.'s shares ended the day 1.34% higher at $59.04 with a total trading volume of 8.87 million shares, which was above their three months average of 7.24 million shares. The stock has gained 14.06% in the previous three months. The Company's shares are trading above their 50-day moving average by 8.78%. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have an RSI of 70.09 and have a dividend yield of 2.71%.
On July 23rd, 2018, Bristol-Myers Squibb announced that Murdo Gordon, Executive Vice President and Chief Commercial Officer, is leaving the Company, effective August 03rd, 2018, to pursue another opportunity. The announcement of a new Chief Commercial Officer will be the subject of a separate communication at a later date. Stock Trader Report's downloadable research report on BMY available at:
https://stocktraderreport.com/registration/?symbol=BMY
--
Stock Trader Report:
Stock Trader Report (STR) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. STR has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
STR has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by STR. STR is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
STR, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. STR, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, STR, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither STR nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://stocktraderreport.com/privacy-policy/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: 917-979-2038
Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Stock Trader Report
Share this article